Champix (Nitrosamine Impurity)

Phil Davis v. Pfizer Canada ULC et al, SCBC No. S218270, Vancouver Registry

All persons resident in Canada who were prescribed, purchased and/or ingested certain Champix prescription medications manufactured and/or packaged by the Defendants that have been recalled due to the presence of a nitrosamine impurity above acceptable limits, and their beneficiaries (the “Class Members”) pursuant to the Family Compensation Act, R.S.B.C. 1996, c. 126.


This proposed class action arises out of concerns for Champix prescription medications, which are used as smoking cessation-medication in adult patients.

The claim alleges that an nitrosamine impurity, (N-nitrosovarenicline) has been detected in certain Champix pills manufactured, distributed and sold by the Defendants at levels higher than recommended under established international guidelines. The nitrosamine impurity is considered a mutagen – a chemical substance that can cause a change in the DNA of a cell. These mutations may increase the risk of cancer.

A link to the Health Canada recall can be found here, which includes a full list of affected products.

Please see the Notice of Civil Claim for more details.



Note: If you received any of the above-listed drugs, you may be affected by this class action lawsuit. Please fill out the form below to get in touch with us. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.

I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing

Class Action Form

Contact Information